PL2320933T3 - Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca - Google Patents

Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca

Info

Publication number
PL2320933T3
PL2320933T3 PL09813336T PL09813336T PL2320933T3 PL 2320933 T3 PL2320933 T3 PL 2320933T3 PL 09813336 T PL09813336 T PL 09813336T PL 09813336 T PL09813336 T PL 09813336T PL 2320933 T3 PL2320933 T3 PL 2320933T3
Authority
PL
Poland
Prior art keywords
neuregulin
subsequence
prophylaxis
treatment
heart failure
Prior art date
Application number
PL09813336T
Other languages
English (en)
Polish (pl)
Inventor
Anthony Caggiano
Anindita Ganguly
Jennifer Iaci
Tom Parry
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of PL2320933T3 publication Critical patent/PL2320933T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL09813336T 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca PL2320933T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
PCT/US2009/004130 WO2010030317A2 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
EP09813336.6A EP2320933B1 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
PL2320933T3 true PL2320933T3 (pl) 2018-07-31

Family

ID=42005671

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09813336T PL2320933T3 (pl) 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca
PL17209369T PL3338791T3 (pl) 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17209369T PL3338791T3 (pl) 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP3632459A1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN104623633A (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK2320933T3 (enExample)
ES (2) ES2763184T3 (enExample)
MX (2) MX2011000696A (enExample)
PL (2) PL2320933T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632459A1 (en) * 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
EP3777878A1 (en) 2008-08-15 2021-02-17 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
PL2488194T3 (pl) 2009-10-14 2016-11-30 Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP2830645B1 (en) * 2012-03-30 2017-08-30 Acorda Therapeutics, Inc. Neuregulin for use in treating peripheral nerve injury
AU2014225534A1 (en) * 2013-03-06 2015-09-24 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
US20180296642A1 (en) 2015-09-25 2018-10-18 Douglas B. Sawyer Methods for treating cardiac injury
CN108778315A (zh) * 2016-04-19 2018-11-09 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) 用于治疗和/或预防神经系统肿瘤的神经调节素
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
KR20220066116A (ko) * 2019-09-16 2022-05-23 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 재조합 인간 뉴레귤린 유도체 및 그의 용도
US20250241989A1 (en) * 2021-10-22 2025-07-31 The Research Institute At Nationwide Children's Hospital Neuregulin for Protection Against Respiratory Viral Infection and Post-Viral Disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
HK1040363B (en) 1998-09-25 2007-01-26 Cubist Pharmaceuticals Llc Use of daptomycin
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AU1916301A (en) 1999-11-12 2001-06-06 Children's Medical Center Corporation Methods for administration of therapeutic agents on an antiangiogenic schedule
EP2357004B1 (en) 2000-05-23 2016-10-12 CeNeS Pharmaceuticals, Inc. NRG-2 nucleic acid molecules, polypeptides and diagnostic and therapeutical methods
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
AU2003210549A1 (en) 2002-01-18 2003-09-02 Chiron Corporation Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20070032557A1 (en) * 2005-02-18 2007-02-08 Matti Kivikko Method for administering levosimendan
US20080279865A1 (en) 2005-03-23 2008-11-13 Pfizer, Inc., Pfizer Products, Inc. Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
BRPI0908271A2 (pt) 2008-02-29 2017-06-13 Acorda Therapeutics Inc método para alcançar níveis plasmáticos desejados de fator de crescimento glial
EP3632459A1 (en) * 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
PL2488194T3 (pl) 2009-10-14 2016-11-30 Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego
EP2603221A4 (en) 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION
EP2830645B1 (en) 2012-03-30 2017-08-30 Acorda Therapeutics, Inc. Neuregulin for use in treating peripheral nerve injury

Also Published As

Publication number Publication date
EP3338791A1 (en) 2018-06-27
MX2011000696A (es) 2011-07-29
BRPI0916442A2 (pt) 2018-06-19
RU2014141514A (ru) 2016-05-10
CN107019794A (zh) 2017-08-08
RU2020111236A3 (enExample) 2021-09-21
RU2020111236A (ru) 2021-09-21
CA2731113A1 (en) 2010-03-18
US9198951B2 (en) 2015-12-01
JP5797112B2 (ja) 2015-10-21
EP2320933A1 (en) 2011-05-18
RU2536938C2 (ru) 2014-12-27
RU2698090C2 (ru) 2019-08-22
US20110166068A1 (en) 2011-07-07
CN104623633A (zh) 2015-05-20
HK1256637A1 (en) 2019-09-27
CN107019794B (zh) 2021-03-12
RU2719199C1 (ru) 2020-04-17
AU2017203528A1 (en) 2017-06-15
JP2015129137A (ja) 2015-07-16
DK3338791T3 (da) 2019-12-16
US9956266B2 (en) 2018-05-01
RU2011105821A (ru) 2012-08-27
EP3632459A1 (en) 2020-04-08
US20180280477A1 (en) 2018-10-04
PL3338791T3 (pl) 2020-04-30
ES2763184T3 (es) 2020-05-27
CN102159236A (zh) 2011-08-17
WO2010030317A2 (en) 2010-03-18
US20160113999A1 (en) 2016-04-28
EP2320933B1 (en) 2017-12-27
DK2320933T3 (en) 2018-04-16
US20130324466A1 (en) 2013-12-05
JP2011528353A (ja) 2011-11-17
JP6189879B2 (ja) 2017-08-30
EP3338791B1 (en) 2019-09-18
EP2320933A4 (en) 2013-02-27
AU2009292216B2 (en) 2015-03-05
US20200009228A1 (en) 2020-01-09
AU2009292216A1 (en) 2010-03-18
ES2664394T3 (es) 2018-04-19
JP2022023208A (ja) 2022-02-07
AU2015202877B2 (en) 2017-03-09
US11235031B2 (en) 2022-02-01
MX384378B (es) 2025-03-14
JP2017200949A (ja) 2017-11-09
AU2015202877A1 (en) 2015-06-18
JP2019196370A (ja) 2019-11-14

Similar Documents

Publication Publication Date Title
PL2320933T3 (pl) Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca
IL259475A (en) Combined therapy for the treatment of diabetes
GB2465897B (en) Respiratory disease treatment
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
SI2154969T1 (sl) Zdravljenje sinukleinopatij
EP2575669A4 (en) SUPPORTED DENTAL IMPLANT TREATMENT
HUE038042T2 (hu) PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
HUE043235T2 (hu) Terápiás kezelések tüdõbetegségekhez
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2429558A4 (en) MEDICINE FOR GAS TREATMENT PROPHYLAXIS
IL217185A0 (en) Medicinal carbohydrates for treatment of respiratory conditions
GB0806047D0 (en) Treatment of heart failure
ZA201207696B (en) Compound for treatment of respiratory condition or disease
GB0816662D0 (en) Treatment of heart failure
GB0804320D0 (en) Treatment of heart failure
GB0901832D0 (en) Respiratory disease treatment
GB0910944D0 (en) Respiratory disease treatment
GB0901831D0 (en) Respiratory disease treatment
GB0814488D0 (en) Respiratory disease treatment
GB0823568D0 (en) Respiratory disease treatment
GB0802903D0 (en) Treatment of diabetes